Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 1.00 |
| ▸ | PARP1 | P09874 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176850 | 1.00 | TNKS2 (1.00) | TNKS2PARP1KMT2APDE10AMAPT | |
| SCHEMBL5794718 | 0.86 | PARP1 (0.82) | TNKS2PARP1KMT2APDE10AMAPT | |
| SCHEMBL29431542 | 0.86 | PARP1 (0.82) | TNKS2PARP1KMT2APDE10AMAPT | |
| SCHEMBL16404338 | 0.85 | PDE10A (0.84) | TNKS2PARP1KMT2APDE10AMAPT | |
| SCHEMBL168776 | 0.83 | PARP1 (1.00) | TNKS2PARP1KMT2APDE10ARAB9A | |
| SCHEMBL29900512 | 0.83 | PARP1 (1.00) | TNKS2PARP1KMT2APDE10ARAB9A | |
| SCHEMBL2999541 | 0.82 | TNKS2 (0.69) | TNKS2PARP1KMT2APDE10AMAPT | |
| SCHEMBL1586541 | 0.82 | PARP1 (0.91) | TNKS2PARP1KMT2APDE10ARAB9A | |
| SCHEMBL14266777 | 0.82 | TNKS2 (0.69) | TNKS2PARP1KMT2APDE10AMAPT | |
| SCHEMBL1685046 | 0.82 | TNKS2 (0.70) | TNKS2PARP1KMT2APDE10AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| CN-112174899-B | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2023-01-17 | — | — | CN | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-20220017474-A1 | Novel Polycyclic Compound | EUTEC NEW MATERIALS TECHNOLOGY (SUZHOU) CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-109384731-B | Method for preparing quinazolinone from enol | 南京理工大学 | 2021-10-08 | — | — | CN | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008572-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112174899-A | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2021-01-05 | — | — | CN | disclosed |
| US-6310069-B1 | INTERMEDIATES TO AZOLIDINEDIONE ANTIDIABETIC COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-10-30 | — | — | US | disclosed |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2001-10-18 | — | — | US | disclosed |
| EP-1073643-A2 | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-02-07 | — | — | EP | disclosed |
| US-6114526-A | REACTING AN AMINO DERIVATIVE WITH A HETEROCYCLIC DIONE COMPOUND TO FORM AN ANTIDIABETIC AGENT | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-09-05 | — | — | US | disclosed |
| EP-0958296-A1 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-24 | — | — | EP | disclosed |
| US-5985884-A | TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-16 | — | — | US | disclosed |
| US-5885997-A | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-03-23 | — | — | US | disclosed |
| WO-1999008501-A2 | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-02-25 | — | — | WO | disclosed |
| WO-1997041097-A2 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-11-06 | — | — | WO | disclosed |
| US-4283407-A | ANTIHYPERTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | AHR, ARNT, MTNR1A | TNKS2 4224/4885PARP1 4174/4885KMT2A 2380/4885 |
| US-11021708-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | TNKS2 944/4885PARP1 1491/4885KMT2A 2256/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | TNKS2 944/4885PARP1 1491/4885KMT2A 2256/4885 |
| US-11008572-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | TNKS2 944/4885PARP1 1491/4885KMT2A 2256/4885 |
| US-20220017474-A1 | Novel Polycyclic Compound | CUTA, DSG1, UACA | TNKS2 1752/4885PARP1 399/4885KMT2A 2775/4885 |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | TNKS2 2708/4885PARP1 4765/4885KMT2A 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.